diet drugs – Diet Business Watch

Weight Watchers Collaborates With Google Health Enterprise

October 1, 2026 Weight Watchers announced a collaboration with Google Health Enterprise, combining wearable technology and AI-powered health insights with Weight Watchers’ clinical weight health program. Available now through select Weight Watchers for Business client programs, this collaboration provides employers and payers a new way to activate their weight health benefits, helping more members get […]

Weight Watchers Collaborates With Google Health Enterprise Read More »

Medifast Reports Q2 2026 Results

News / John LaRosa

June 30, 2026 Management reported Medifast Q2 results, as follows: Second Quarter 2026 • Revenue: $76.4 million, with revenue per active earning coach of $6,529 • Independent active earning coaches of 11,700 • Net loss of $3.1 million or $0.28 loss per diluted share (“EPS”) • Cash, Cash Equivalents, and Investment Securities of $169.8 million

Medifast Reports Q2 2026 Results Read More »

Weight Watchers Reports Q2 Results

News / John LaRosa

August 5, 2026 WW reported its Q2 results today. Management said: “We view 2026 as a year of focused transition for Weight Watchers, and our Q2 results reflect that work taking hold across the business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “Core+, our high-value

Weight Watchers Reports Q2 Results Read More »

Weight Watchers Reports Q1 2026 Results

News / John LaRosa

May 7, 2026 According to management: “We remain confident in our strategy to build the industry-leading weight health platform. Our focus is on executing high-impact initiatives that drive Clinical growth and stabilize our Behavioral business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “We made encouraging

Weight Watchers Reports Q1 2026 Results Read More »

New Eli Lilly Weight Loss Pill Approved – Foundayo

News / John LaRosa

April 2, 2026 On April 1, 2026, the FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill developed by Eli Lilly for adults with obesity or overweight and at least one weight-related condition. Unlike other options, Foundayo does not require fasting or specific timing. It mimics a natural hormone to regulate appetite and,

New Eli Lilly Weight Loss Pill Approved – Foundayo Read More »

U.S. Weight Loss Market Now Worth $135 Billion – New Report

News / John LaRosa

March 4, 2026 Marketdata LLC has released a new report: “The U.S. Weight Loss Market: Status Report & 2026 Forecast” This 108-page analysis tracks the current status of ALL weight loss market segments, 2025 performance, the latest dieting trends, 15 competitor profiles, with 27 tables and charts. Some findings: The total U.S. weight loss market

U.S. Weight Loss Market Now Worth $135 Billion – New Report Read More »

Medifast Reports Q4 and Full Year 2025 Results

News / John LaRosa

Feb. 18, 2026 Medifast reported full-year and Q4 2025 results on February 17, 2026. 2025 revenues came in at $386 million – a 36% decrease from $602 million in 2024. The company employed 16,100 active earning Optavia health coaches, who had quarterly earnings of $4,664 (or $18,656 on an annual rate). “As we enter 2026,

Medifast Reports Q4 and Full Year 2025 Results Read More »

Telehealth Companies Offer Novo’s Wegovy pill

News / John LaRosa

Jan. 6, 2026 Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday Jan. 5. The firm aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through April 15. It’s also trying to onboard new patients through a growing number

Telehealth Companies Offer Novo’s Wegovy pill Read More »

FDA Approves Novo’s Wegovy Weight Loss Pill

News / John LaRosa

Dec. 22, 2025 The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — called the Wegovy pill — is the “first and only” oral GLP-1 medicine, or glucagon-like peptide-1, receptor agonists, according to Novo

FDA Approves Novo’s Wegovy Weight Loss Pill Read More »

Trump Cuts Deal To Lower Weight Loss Drug Prices

News / John LaRosa

Nov. 6, 2025 CNBC reported today that President Donald Trump announced deals with Eli Lilly and Novo Nordisk and Eli Lilly toslash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatment. The agreements will cut prices of so-called GLP-1 drugs for

Trump Cuts Deal To Lower Weight Loss Drug Prices Read More »